西尔德纳菲尔和阿尔茨海默病风险:系统性审查和元分析
Wei Yu Chua1, Lincoln Kai En Lim1, James Jia Dong Wang2
1Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Aging
|March 17, 2025
概括
西尔德纳菲尔使用与阿尔茨海默病 (AD) 的风险降低两倍有关. 这一元分析表明,西尔德纳菲尔在抗阿兹海默症发展方面具有潜在的保护作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 阿尔茨海默病 (AD) 在全球影响超过5000万,每年有1000万新病例.
- 西尔德纳菲尔 (一种固酶-5抑制剂) 与AD风险之间的关系正在调查中.
- 这项研究是首次对西尔德纳菲尔使用和AD风险进行元分析.
研究的目的:
- 进行对西尔德纳菲尔使用与患阿尔茨海默病的风险之间的关联进行元分析.
- 综合现有研究的证据,以确定西尔德纳菲尔使用是否影响AD发病率.
主要方法:
- 搜索了MEDLINE和Embase数据库,从创建到2024年3月11日.
- 包括队列和病例控制研究,比较了在西尔德纳菲尔使用者和非使用者的AD频率.
- 使用随机效应的元分析,汇集风险比率 (RR) 和危险比率 (HR).
主要成果:
- 分析了5项涉及885,380名患者的研究.
- 西尔德纳菲尔使用与AD风险降低两倍相关 (HR:0.47,95%CI:0.27-0.82).
- 固酶-5抑制剂也显示AD的风险降低 (RR:0.55,95%CI:0.38-0.80).
结论:
- 西尔德纳菲尔的使用显着与患阿尔茨海默病的风险降低有关.
- 建议进行进一步的随机对照试验,以确认西尔德纳菲尔对AD病理学的影响.
相关概念视频
01:22Alzheimer's Disease: Treatment
139
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
139
01:26Alzheimer's Disease: Overview
405
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
405
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
121
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
121
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
87
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
87
01:30Dementia
81
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
81